<DOC>
	<DOCNO>NCT01247480</DOCNO>
	<brief_summary>Major Aims study : 1 . To create gene expression-based prognostic device complement exceed prognostic utility conventional biomarkers breast cancer outcome . 2 . To identify one clinical subgroup patient prognostic device outperforms , substantially add , prognostic performance conventional marker currently determine therapeutic strategy . Sub-Aims study : 1 . Assess prognostic value multiple gene expression signature , alone combination , use large cohort breast cancer patient pathology , treatment outcome available . A `` training '' `` test '' design propose . 2 . Evaluate utility prognostic device measure gene expression level formalin-fixed paraffin-embedded specimen ( FFPEs ) primary resect tumor . The investigator utilize Affymetrix Quantigene 2.0 Assay and/or Illumina BeadXpress VeraCode DASL Gene Expression Assay ( FDA-approved IVDMIA . ) 3 . For specific clinical subgroup patients/tumors , investigator mathematically identify additive synergistic prognostic relationship gene gene signature , combination , yield maximal risk prediction ( distant metastases-free survival ) patient . 4 . Compare prognostic utility investigator device conventional prognostic variable currently use determine therapeutic strategy . 5 . Incorporate prognostic signature practical prognosis algorithm seek include conventional measure outcome tumor size , histologic grade , nodal status , patient age , Nottingham index , etc . The investigator hypothesize adequate quality quantity tumor RNA may extract archival paraffin-embedded tumor specimen gene expression profiling , archival tumor-derived genomic signature may use prognosticator predictor breast cancer .</brief_summary>
	<brief_title>Analysis Prognostic Predictive Genomic Signatures Using Archival Paraffin-embedded Tumor Specimens Breast Cancer</brief_title>
	<detailed_description>800 breast cancer patient fulfill eligibiltiy criterion select NUH breast cancer registry ( 400 training , 400 validation ) . Eligible patient least 5 year ' follow-up NUH available archival paraffin-embedded tumor block store Department Pathology , NUH . 8-10 ten-micron section tumor block cut RNA extract section . RNA profile use high-throughput gene expression platform ( Illumina Veracode assay , Affymetrix Quantigene assay ) . Raw gene expression data apply follow signature previously generate Genome Institute Singapore : 1 . 32-gene p53 Pathway Signature 2 . 5-gene Genetic Grade Signature 3 . 33-gene TuM1 Signature 4 . 10-gene ER Signature ( Miller &amp; Tan , et . al. , unpublished ) 5 . 6-gene 3-Ratio Predictor ( Miller &amp; Karuturi , et . al. , unpublished ) 6 . 5-gene HER2 Amplicon Predictor ( Miller &amp; Karuturi , et . al. , unpublished ) 7 . 7-gene Basal-Luminal Discriminator ( Miller , unpublished ) The prognostic and/or predictive ability signature compare conventional clinical prognosticator predictor goal develop archival tumor-derived genomic test breast cancer management future . The archival paraffin-embedded tumor block left-over sample clinical use . They sample consent research purpose . We request waiver consent minimal risk study . We ensure sufficient tissue leave behind future routine diagnostic purpose . Sections take tumor cod patient identifier protect privacy confidentiality participant . The result generate tumor sample study impact clinical management patient .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Eligible patient least 5 year ' followup NUH available archival paraffinembedded tumor block store Department Pathology , NUH Non breast cancer patient</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>